Publications &
Presentations

September 2004
European Academy of Dermatology and Venereology (EADV) Congress

CLE-400: Topical α2-adrenergic agonist being developed as a novel mechanism for treating chronic pruritus associated with Notalgia Paresthetica
Orna Goren, PhD

Learn More
CLE
400
September 2024
7th Neuropsychiatric Drug Development Summit

Introducing CLE-905, a Potent Dual M1/M4 Receptor Agonist in Development for Treatment of Schizophrenia and Additional Psychiatric Disorders
Hadile Ounallah-Saad, PhD

Learn More
CLE
905
November 2023
7th Annual Dermatology Drug Development Summit

Introducing CLE-400; Topical Alpha-2-Adrenergic Agonist as a First-in-Class Treatment for Localized Chronic Pruritus
Mary Spellman, M.D.

Learn More
CLE
400
May 2023
American Society of Clinical Psychopharmacology (ASCP) 2023

A Phase 2 Randomized Controlled Adjunctive Treatment Trial with CLE-100 Esketamine Tablet for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants, During the COVID-19 Pandemic
Maurizio Fava, Oren Berkowitz, Sanjay J. Mathew, Michael E. Thase, Andrew A. Nierenberg, Dan V. Iosifescu, L. Alison McInnes, Cristina Cusin, Robert Berman, Eli Eyal, Ari Gershon, Esther Lukasiewicz-Hagai

Learn More
CLE
100
September 2022
2022 European Society for Dermatology Research ESDR Annual Meeting

High Unmet Medical Need in Brachioradial Pruritus: Results from a Large Patient Survey
Elinor Artsy Navon, MD

Learn More
CLE
400
September 2022
International Congress of Parkinson's Disease and Movement Disorders

Dysphagia and its Relationship to Medication Intake in Parkinson's Disease
Elijahu Berkovich, PhD and Dorit Mimrod, PhD

Learn More
CLE
600
July 2022
CRS 2022 Annual Meeting & Expo

OLAR®: A Novel Oral Long Acting Release (OLAR®) platform
Menashe Levy

Learn More
OLAR®
May 2022
IAPRD Congress 2022

Sleep problems in Parkinson’s Disease: PD patients’ survey on common issues and treatments expectations
Elijahu Berkovich, PhD

Learn More
CLE
600
October 2021
International Forum for the Study of Itch (IFSI) World Congress on Itch

CLE-400 for Chronic Neuropathic Itch
Yael Rosen, MD

Watch Video
CLE
400
September 2021
International Parkinson and Movement Disorder Society (MDS)

CLE-600: Treating nocturnal and early morning OFF symptomology in Parkinson's disease with the OLAR platform Elijahu Berkovich, PhD

Learn More
CLE
600
June 2021
International Association for the Study of Pain (IASP) 2021 Virtual World Congress on Pain

CLE 400 a potent alpha 2 adrenergic receptor agonist for the treatment of chronic itch
Elanite Caspi, PhD

Learn More
CLE
400
June 2021
International Association for the Study of Pain (IASP)

CLE-400 a Potent Analgesic Topical Gel in Acute and Chronic Pain Pig Models.
Elanite Caspi, PhD

Learn More
CLE
400
May 2021
Society for Investigative Dermatology (SID)

CLE-400 a potent alpha 2 adrenergic receptor agonist for the treatment of chronic itch
Johanna Schumann, PhD

Learn More
CLE
400
May 2021
International Association of Parkinsonism and Related Disorders (IAPRD)

CLE-600: Treating nocturnal and early morning OFF symptomology in Parkinson’s disease with the OLAR® platform
Elijahu Berkovich, PhD

Learn More
CLE
600
May 2021
SMi - 21st Annual Conference Pain Therapeutics - Virtual

CLE-400 a novel non-opioid topical treatment for painful diabetic neuropathy
Orna Goren, PhD

Learn More
CLE
400
March 2021
Drug Delivery & Formulation (DDF) Summit

Introducing the OLAR platform
Elijahu Berkovich, PhD

Learn More
OLAR®
Skip to content